← Back to searchRecruitingRecruiting
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
NCT05218850 · Children's Hospital Los Angeles
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Butyrate Therapy in Hispanic Children With Ulcerative Colitis
About this study
butyrate enemas will be administered for 12 weeks to children ages 7 to 21 with mild to moderate ulcerative colitis to determine if butyrate therapy can help improve the clinical disease in those children. standard management of the disease will be performed during these 12 weeks including routine laboratory studies and endoscopy.
Eligibility criteria
Inclusion Criteria:
* 7-21 years, mild to moderate ulcerative colitis
Exclusion Criteria:
* UC therapy within 4 weeks of study medication initiation
* infectious colitis, -pregnancy
Study design
Enrollment target: 10 participants
Allocation: na
Masking: none
Age groups: child, adult
Timeline
Starts: 2022-06-29
Estimated completion: 2027-06-30
Last updated: 2024-04-18
Interventions
Drug: Butyrate
Primary outcomes
- • remission of clinical disease (12 weeks)
Sponsor
Children's Hospital Los Angeles · other
Contacts & investigators
ContactSonia Michail, MD · contact · sonia.michail@hotmail.com · 3233611353
InvestigatorSonia Michail, MD · principal_investigator, Children's Hospital Los Angeles
All locations (1)
Children's Hospital Los AngelesRecruiting
Los Angeles, California, United States